Navigation Links
Lumiracoxib Study Showed Significantly Less Impact on Blood,Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension

mately four hours and in this study showed similar efficacy in a once-daily dose compared to ibuprofen given three times a day.

The clinical trial database for lumiracoxib comprises approximately 40,000 patients, making it one of the largest bodies of evidence for any drug in its class. This includes the results of TARGET (Therapeutic Arthritis Research and Gastrointestinal Trial) involving more than 18,000 patients. Results of this trial showed lumiracoxib also significantly reduced the incidence of upper gastrointestinal complications by 79% in patients not taking aspirin compared to ibuprofen and naproxen.

In TARGET, serious adverse events were reported in 6% of patients receiving lumiracoxib, the same rate seen in patients receiving ibuprofen or naproxen. Adverse events requiring study discontinuation occurred in 16% of lumiracoxib patients and 18% of NSAID patients.

The most frequently occurring gastrointestinal (GI) events were dyspepsia (25% of lumiracoxib patients compared with 26% of NSAID patients) and upper abdominal pain (10% vs. 13%). All other GI events occurred in less than 10% of patients in both groups. In an analysis of cardiovascular outcomes in TARGET, the incidence of events -- defined as non-fatal and silent myocardial infarction, stroke, or cardiovascular death -- was low and comparable in both groups. At one year, there were 59 events in the group of patients taking lumiracoxib (0.65%) and 50 events in the group taking NSAIDs (0.55%, p=0.5074).

Disclaimer

The foregoing press release contains forward-looking statements such as "can," "may," or similar expressions, or by express or implied discussions regarding potential future regulatory filings or approvals or potential future sales of lumiracoxib. Such forward-looking statements reflect the current views of Novartis regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with lumiracoxib to
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:3/31/2015)... -- Accelerated orthodontic treatment will be a featured ... Annual Session, May 15-19, as seven of the ... ® . Manufactured by OrthoAccel ® Technologies, ... a FDA-cleared, Class II medical device that speeds ... percent with just 20 minutes of daily use. ...
(Date:3/31/2015)... -- SCILEX Pharmaceuticals, Inc., a company engaged in the development ... pain, today announced that ITOCHU CHEMICAL FRONTIER Corporation (ICF, ... ITOCHU Corporation ( Tokyo : 8001; OTC-PINK: ... trading companies) in Japan , has ... closely with SCILEX as an advisor and development partner ...
(Date:3/31/2015)... , March 31, 2015  SynCardia Systems, Inc. has ... (IDE) clinical study on the effective use of its ... The FDA approval will ... as 30 heart failure patients. Patients enrolled in this ... as a bridge to a donor heart transplant. ...
Breaking Medicine Technology:Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 2Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 3SCILEX Pharmaceuticals Announces Strategic Investment By ITOCHU CHEMICAL FRONTIER Corporation 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 3FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 4
... March 2, 2011 Warner Chilcott plc (Nasdaq: ... subsidiaries are seeking to refinance the Company,s existing credit ... (the "Existing Credit Agreement"), by entering into a new ... refinancing is expected to have the effect of extending ...
... take non-steroidal anti-inflammatory drugs three times a day for more ... erectile dysfunction compared to men who do not take those ... in The Journal of Urology . ... this observational study used electronic health records, an automated pharmacy ...
Cached Medicine Technology:Warner Chilcott Seeks to Refinance its Existing Credit Agreement 2Warner Chilcott Seeks to Refinance its Existing Credit Agreement 3Non-Steroidal Anti-Inflammatory Drugs Linked to Increased Risk of Erectile Dysfunction 2Non-Steroidal Anti-Inflammatory Drugs Linked to Increased Risk of Erectile Dysfunction 3
(Date:4/1/2015)... 01, 2015 Decora Preset 30 Minute Countdown ... on ‘The Hardware City.’ The product helps in automatically switching ... time and the related electronic device is automatically turned off ... the company said, “We are glad that this amazing product ... buy Countdown Timer Switch in just a few clicks. The ...
(Date:4/1/2015)... CA (PRWEB) April 01, 2015 San ... and the international children’s medical charity, Operation Smile, ... new global partnership. , Campaign Details: RxOrganics is ... Rxmedical line to Operation Smile throughout 2015. RxOrganics ... on such sales so that every order placed online ...
(Date:4/1/2015)... April 01, 2015 TCS Healthcare Technologies ... for the care management and population health arenas, is ... portal Acuity Connect, which is fully integrated with the ... 2015 at 1:30 p.m. ET, will be led by ... TCS. It will explore the feature-rich portal as well ...
(Date:4/1/2015)... Rafael, CA (PRWEB) April 01, 2015 ... College Golf Development Camps in Arizona and Florida. These ... looking to lower their score in a golf-intensive environment ... coaching staff, led by University of Arizona coaching legend, ... the student-athlete on the knowledge gaps as it pertains ...
(Date:4/1/2015)... Poisonous plants (poison ivy, oak and ... recent years, increasing significantly in number and rash-causing potency. ... to poison plants (according to the American Academy of ... summer adventures in nature, they should be aware that ... greater than ever. This year, Ivarest adds a new ...
Breaking Medicine News(10 mins):Health News:Leviton Decora Preset 30 Minute Countdown Timer Available On TheHardwareCity.com 2Health News:RxOrganics Forges Unique Partnership to Bring More Smiles to Underserved Global Heath Communities 2Health News:TCS Healthcare Technologies Releases Acuity Connect 2Health News:TCS Healthcare Technologies Releases Acuity Connect 3Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 2Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 3Health News:New Ivarest Poison Ivy Itch Spray Provides All-Day Comfort 2
... NEW YORK, Dec. 26 Immtech Pharmaceuticals,Inc. (Amex: ... working with clinical,investigators at the South African site ... (DB289), an investigational therapy. In preliminary,findings from the ... following treatment with pafuramidine. The Company has discussed,the ...
... Affiliates,(SCA), one of the country,s largest providers of ... into a joint venture,relationship with University of California ... operation of the existing UTC SurgiCenter located at ... center will operate,under the new name, University Ambulatory ...
... Calif., Dec. 26 Varian Medical,Systems, Inc., (NYSE: ... the acquisition,of Pan-Pacific Enterprises, Inc., the largest independent ... purpose of marketing, sales, and,distribution of Varian X-ray ... held business for approximately $2 million in cash ...
... It wasn,t that long ago that,pharma companies were ... direction and across the pharma industry companies are now,shrinking ... a constant,state of flux, the fundamentals of selling remain ... it is the practices that reps follow within these ...
... joins USDA guidance on nutrition and healthy weight , ... the new U.S. Department of Agriculture,s food pyramid (MyPyramid), ... of their food guide pyramid for older adults. , ... foods and the importance of fluid balance but now ...
... filariasis, trachoma, leishmaniasis, onchocerciasis, schistosomiasis and other so-called ... burdens, especially among the worlds poorest people. Together, ... which are caused by worms or other parasites, ... people of quality of life and life itself ...
Cached Medicine News:Health News:Immtech Announces Pafuramidine (DB289) Program on Clinical Hold 2Health News:Immtech Announces Pafuramidine (DB289) Program on Clinical Hold 3Health News:Surgical Care Affiliates and UCSD Medical Center to Partner in Surgical Center 2Health News:Varian Medical Systems Acquires Pan-Pacific Enterprises for Marketing, Sales and Distribution of X-Ray Imaging Products in China 2Health News:Varian Medical Systems Acquires Pan-Pacific Enterprises for Marketing, Sales and Distribution of X-Ray Imaging Products in China 3Health News:Pharmaceutical Sales: Best Practices for Pharmaceutical Sales Success 2Health News:Food Pyramid for Older Adults Gets an Update 2Health News:Neglected tropical diseases burden those overseas, but travelers also at risk 2
... Equally Spaced, Expandable, Multichannel Pipettor ... instantly boosts productivity with an industry breakthroughequal ... adjustment of a slide rod. This innovation ... liquids between vessels with different configurations. ...
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
... Ergonomic Design for Unparalleled Comfort ... it. Notice the balance. Notice the trigger and ... left-handed. Thats because our pipettors are ergonomically designed ... long hours of pipetting. Productivity In The ...
... Ergonomic Design for Unparalleled Comfort Pick one ... the balance. Notice the trigger and ejector positionsright ... because our pipettors are ergonomically designed to help ... of pipetting. Productivity In The Palm Of ...
Medicine Products: